Detalhe da pesquisa
1.
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
Ann Oncol
; 32(2): 269-278, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33130216
2.
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Ann Oncol
; 29(9): 1918-1925, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30016392
3.
EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patients.
ESMO Open
; 7(5): 100550, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35994790
4.
Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications.
ESMO Open
; 6(2): 100072, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676294
5.
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population.
NPJ Precis Oncol
; 5(1): 69, 2021 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34285332
6.
EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.
Eur J Cancer
; 117: 60-68, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31254940
7.
TARGET National: A UK-wide Liquid-based Molecular Profiling Programme: On Behalf of the TARGET National Consortium.
Clin Oncol (R Coll Radiol)
; 35(1): 33-37, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335040
8.
Response to comment on "Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications".
ESMO Open
; 6(6): 100307, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794056
9.
Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population.
NPJ Precis Oncol
; 5(1): 86, 2021 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34535754